About "Health Research Institute"
The PwC health research institute focuses on large scale issues and major developments and includes analysis on healthcare trends as well as key insights and industry best practices.
More about this author
- Medical Cost Trend: Behind the numbers 2015
6/26/14 | Health Research Institute
The story of 2015 is a nuanced one. At first glance, the health sector appears to be reverting to historical patterns of bouncing back as the nation recovers from the economic doldrums. Whether spending more freely because of the improved economy or shopping with insurance provided through the Affordable Care Act, consumers triggered the first bump in growth in the first quarter of 2014. We expect that to continue through next year.
- Healthcare provider: 2013 SEC comment letter trends
1/6/14 | Health Research Institute
To help registrants gain insight into the SEC’s current areas of interest, PwC analyzed comments released by the SEC staff to domestic large accelerated, accelerated and non-accelerated registrants within the healthcare provider industry during the three year period ended September 30, 2013.
- Top health industry issues of 2014
12/11/13 | Health Research Institute
The 2014 Top Issues report examines the shifting healthcare landscape and offers insights on how to survive rising expectations and tough competition.
- Pharmaceutical and Life Sciences: 2013 SEC comment letter trends
10/23/13 | Health Research Institute
Pharmaceutical and Life Sciences - 2013 SEC comment letter trend compiles and analyzes the SEC staff’s comment letters issued over the past few years to registrants across different sectors within the Pharmaceutical and Life Sciences industry and provides highlights surrounding current hot topics and sample comments.
- Medtech companies prepare for an innovation makeover
10/10/13 | Health Research Institute
The mere concept of innovation needs redefining in a health ecosystem that demands and rewards new models for delivering better care across a broader patient population at lower costs. Medtech companies must get ready to compete in this new environment or risk being displaced by ones that can show evidence their innovations achieve the same high clinical standards but are faster, better, cheaper, and more integrated into the care delivery continuum.